Stocks · News reference
The9 Says Investee Nanyang Biologics Received SEC Notice Of Effectiveness For Form F-4 Ahead Of Nasdaq Listing At $1.5B Pre-Transaction Valuation; Expects To Own 15% To 16% Of Combined Company
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Information Technology Stocks Moving In Thursday's After-Market Session
Gainers Elastic (NYSE:ESTC) shares increased by 16.9% to $97.92 during Thursday's after-market session. The market value of their outstanding shares is at $8.3 billion. The company's, Q1 earnings came out
The9 Q2 EPS $0.01, Sales $712.000K
The9 (NASDAQ:NCTY) reported quarterly earnings of $0.01 per share. The company reported $712.000 thousand in sales this quarter.
The9 shares are trading higher. The company announced its investee Nanyang Biologics cleared a key step toward a planned Nasdaq listing after RF Acquisition shareholders approved their merger.